Edition:
United Kingdom

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

6.20USD
8:59pm GMT
Change (% chg)

$0.17 (+2.82%)
Prev Close
$6.03
Open
$6.05
Day's High
$6.29
Day's Low
$5.90
Volume
406,014
Avg. Vol
184,179
52-wk High
$15.01
52-wk Low
$4.10

Select another date:

Wed, Dec 6 2017

BRIEF-Insys Therapeutics' NDA For Buprenorphine Sublingual Spray Accepted By FDA

* FDA ACCEPTS NEW DRUG APPLICATION (NDA) FOR BUPRENORPHINE SUBLINGUAL SPRAY FROM INSYS THERAPEUTICS

Billionaire Insys founder can remove ankle monitor -judge

BOSTON, Nov 27 The billionaire founder of Insys Therapeutics Inc, charged with engaging in a scheme to bribe doctors to prescribe an opioid, won the lifting of a requirement that he wear a GPS-enabled ankle monitor on Monday, which he said interfered with jogging.

Billionaire founder of Insys pleads not guilty to opioid bribe scheme

BOSTON The billionaire founder of drugmaker Insys Therapeutics Inc pleaded not guilty on Thursday to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based spray to treat pain in cancer patients.

UPDATE 2-Billionaire founder of Insys pleads not guilty to opioid bribe scheme

BOSTON, Nov 16 The billionaire founder of drugmaker Insys Therapeutics Inc pleaded not guilty on Thursday to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based spray to treat pain in cancer patients.

Billionaire founder of Insys to plead not guilty to opioid bribe scheme

BOSTON, Nov 16 The billionaire founder of Insys Therapeutics Inc was expected to appear in federal court in Boston on Thursday to plead not guilty to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug.

Insys posts loss after founder charged in U.S. opioid bribe case

BOSTON Insys Therapeutics posted a bigger-than-expected quarterly loss on Thursday due to soft demand for its flagship product Subsys, an opioid cancer pain medication at the center of a federal probe of the company.

UPDATE 2-Insys posts loss after founder charged in U.S. opioid bribe case

BOSTON, Nov 2 Insys Therapeutics posted a bigger-than-expected quarterly loss on Thursday due to soft demand for its flagship product Subsys, an opioid cancer pain medication at the center of a federal probe of the company.

BRIEF-Insys Therapeutics reports Q3 loss per share of $2.30

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

Insys Therapeutics posts net loss in third quarter

Nov 2 Insys Therapeutics on Thursday reported a net loss for the third quarter, compared to a year-ago profit, amid an investigation of the U.S. drugmaker's founder on charges of bribery.

Insys founder Kapoor steps down as Akorn chairman after arrest

NEW YORK John Kapoor, the billionaire founder of opioid maker Insys Therapeutics Inc, has resigned as chairman of drugmaker Akorn Inc, just days after his arrest on charges he participated in a scheme to bribe doctors to prescribe a potent pain medication while he was at Insys.

Select another date: